Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
Clin Biochem
; 44(10-11): 869-72, 2011 Jul.
Article
en En
| MEDLINE
| ID: mdl-21565179
OBJECTIVE: Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, have been reported as putative tumor markers because of their involvement in cancer invasion and metastasis. The aim of our study was to elucidate the possible role of MMP-2 and -9 as serum prognostic biomarker for breast cancer classification and correlate it with the clinicopathological variables. DESIGN AND METHODS: Our study consisted of 60 females with primary breast cancer, 40 cases of benign breast disease and 60 healthy female volunteers as controls. The serum MMP-2 and -9 levels were quantitatively measured by ELISA technique. RESULTS: A significantly raised MMP-2 and MMP-9 levels were observed in breast cancer patients. Significant rise in serum MMP-9 concentration was found in patients presenting with metastasis as well as in those cases who presented with a duration of less than 1year. ROC analyses depicted a serum cutoff value of 315ng/mL for MMP-9 to discriminate the breast cancer patients from the control group. CONCLUSION: Our results suggest that serum MMP-9 level is a better marker than serum MMP-2 in predicting the breast cancer development and progression.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Progresión de la Enfermedad
/
Metaloproteinasa 2 de la Matriz
/
Metaloproteinasa 9 de la Matriz
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
Clin Biochem
Año:
2011
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
Estados Unidos